Drugs that contain Ibrutinib
1. List of Imbruvica drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8735403 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US7514444 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8957079 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US9181257 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8697711 | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(4 years from now) | |
| US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476284 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8497277 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8952015 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8703780 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8754091 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(3 years from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8563563 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(4 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(4 years from now) | |
| US10016435 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9814721 | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10478439 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801881 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US8754090 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9125889 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US8999999 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801883 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10004746 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10751342 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10653696 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
| US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(10 years from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(10 years from now) | |
| US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
| US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2029 |
| ODE* (ODE*) | Aug 2, 2024 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Pediatric Exclusivity (PED) | Feb 24, 2030 |
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of marginal zone lymphoma; Treatment of small lymphocytic lymphoma; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of waldenstrom's macroglobulinemia; Treatment of mant...
Dosage: TABLET;ORAL
IMBRUVICA family patents
167
United States
27
Japan
22
European Union
21
Australia
21
Canada
16
Korea, Republic of
16
New Zealand
13
China
12
Israel
10
Singapore
10
Hungary
9
Spain
9
Mexico
8
EA
8
Poland
8
Slovenia
8
South Africa
7
Denmark
7
Cyprus
7
Portugal
7
Taiwan
7
Lithuania
6
Philippines
6
Brazil
5
Hong Kong
4
Chile
4
Argentina
3
Luxembourg
3
Dominican Republic
3
Morocco
2
Ecuador
2
Uruguay
2
Peru
2
Jordan
2
Ukraine
1
Colombia
1
Netherlands
1
Tunisia
1
Malaysia
1
Costa Rica
1
Austria
1
Russia
1
Guatemala
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic